Crestone For Patients
What is CRESTONE?
CRESTONE, or Clinical study of REsponse to Seribantumab in TumOrs with NEuregulin 1 (NRG1) fusions, is a clinical trial opportunity for patients with advanced solid tumors who have not responded, or are no longer responding to standard treatment, and whose tumor has tested positive for the NRG1 fusion.
- Eligibility
- FAQ
- Resources
- Study Sites
Explore
Eligibility
Who is Eligible?
If you can answer “yes” to all of the statements below, you may qualify for the CRESTONE trial. We recommend that you discuss your clinical trial options with your physician.
- I am 18 years of age or older
- I am not currently pregnant, and do not plan to become pregnant soon
- I have an advanced solid tumor
- My cancer is no longer responding to standard anti-cancer treatment, or there is no standard treatment that is available
- I have had a genomic or molecular test performed on my tumor, and the test result shows that my tumor has an NRG1 gene fusion
What if I’m not sure if I meet every eligibility criteria for CRESTONE?
As long as your tumor has an NRG1 gene fusion, you may be eligible to receive seribantumab on an investigational basis. We encourage you to talk to your physician about your clinical trial options and reach out to us with any questions at medicalaffairs@elevationoncology.com or +1 716-371-1125.
How do I find out if my tumor has an NRG1 fusion?
Today, the only way to know for sure if your tumor has an NRG1 fusion is to have your tumor genomically tested.
There are multiple types of tests available today for detecting gene fusions, but some are more sensitive than others. The most sensitive method of detecting an NRG1 gene fusion currently is by getting an RNA-based Next Generation Sequencing (NGS) test that looks at your tumor’s RNA instead of its DNA.
If you have been diagnosed with a solid tumor, we encourage you use the resources below to learn more, and to talk to your physician about your genomic testing options.
FAQ
Frequently Asked Questions about CRESTONE
If you have not yet had your tumor tested for an NRG1 gene fusion, talk to your physician today about available testing options.
If your tumor has tested positive for an NRG1 fusion and you and your physician determine that the CRESTONE study may be the right path forward in your treatment journey, the next step is to find a participating study site near you.
Active sites are listed below in the “Participating CRESTONE study sites” section, and at www.clinicaltrials.gov (NCT04383210). Our team is also available to help identify the best study site for you. Contact us at medicalaffairs@elevationoncology.com or +1 (716) 371-1125, and we will return your message within 48 hours.
Clinical trials like CRESTONE offer access to experimental medicines that may help you and other patients in the future. Because a clinical trial is a rigorously controlled study, you can expect a comprehensive treatment plan with clear milestones and follow-up. Clinical trials are reviewed and approved by study sites to ensure quality of care.
Your physician and the investigators at the clinical trial site will give you a full description of what to expect while you participate in CRESTONE. At any time, feel free to contact us at medicalaffairs@elevationoncology.com or +1 (716) 371-1125 and our medical team will answer any questions that you have.
Your cancer treatment on CRESTONE is provided free of charge to you. In addition, we are committed to assisting our patients with travel and lodging costs. While travel is often necessary, we believe participation in the CRESTONE study should not be a financial burden. Please contact us at medicalaffairs@elevationoncology.com or +1 (716) 371-1125 for specific details and our team will be happy to answer any specific questions that you may have.
Yes, the CRESTONE study is designed so that all patients will receive the investigational drug seribantumab. No patients on CRESTONE will receive a placebo.
Seribantumab is an intravenous (IV) medication that is administered in a hospital, out-patient infusion center based upon the clinical trial site’s facilities and capabilities. Your physician will explain to you the frequency and duration of each administration that you can expect throughout the clinical trial.
Learn More
Patient resources
The following downloadable resources are available to help you and your loved ones learn more about the CRESTONE study. These resources may also be helpful to share with your doctor at your next appointment:
To learn more about genomic testing for cancer and how it can help your doctor better tailor your treatment plan for you, the following resources may be a good place to start:
Find a Location
Participating CRESTONE study sites
The CRESTONE study is open and enrolling patients at the US clinical sites listed below. Most of the clinical sites are part of a larger network, and all questions and/or referrals should be directed to the primary contact at the main operations center.
We are actively opening new sites across the US and will update this list regularly. If you do not yet see a clinical site open near you and would like to learn more about the CRESTONE study, please contact us directly at medicalaffairs@elevationoncology.com or +1 (716) 371-1125. We look forward to hearing from you, and will return your message within 48 hours.
| Clinical Trial Site | City | State | Status |
| University of Alabama at Birmingham | Birmingham | AL | Open and Enrolling |
| Honor Health | Scottsdale | AZ | Open and Enrolling |
| Compassionate Cancer Care | Fountain Valley | CA | Open and Enrolling |
| Pacific Shores Medical Group | Huntington Beach | CA | Open and Enrolling |
| Cedars Sinai | Los Angeles | CA | Open and Enrolling |
| University of California – Irvine Medical Center | Orange | CA | Open and Enrolling |
| University of Colorado | Denver | CO | Open and Enrolling |
| Georgetown University | Washington | DC | Open and Enrollling |
| Advent Health | Orlando | FL | Open and Enrolling |
| Moffit Cancer Center | Tampa | FL | Open and Enrolling |
| University Cancer & Blood Center | Athens | GA | Open and Enrolling |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | IL | Open and Enrolling |
| Massachusetts General Hospital (MGH) | Boston | MA | Open and Enrolling |
| Henry Ford | Detroit | MI | Open and Enrolling |
| Metro Minnesota CCOP | St. Louis Park | MN | Open and Enrolling |
| Washington University at St. Louis | St. Louis | MO | Open and Enrolling |
| Levine Cancer Center | Charlotte | NC | Open and Enrolling |
| Montefiore | Bronx | NY | Open and Enrolling |
| Ohio State University | Columbus | OH | Open and Enrolling |
| Oregon Health and Science University | Portland | OR | Open and Enrolling |
| Sarah Cannon Research Institute (SCRI) | Nashville | TN | Open and Enrolling |
| MD Anderson Cancer Center | Houston | TX | Open and Enrolling |
| Utah Cancer Specialists | Salt Lake City | UT | Open and Enrolling |
| VA Cancer Specialists | Fairfax | VA | Open and Enrolling |
| Northwest Medical Specialists | Tacoma | WA | Open and Enrolling |
| University of Wisconsin | Madison | WI | Open and Enrolling |
Getting Started in the Trial
Talk with your physician about tumor testing and clinical trials
If you are interested in getting your tumor tested and learning about investigational therapies that may be uniquely targeted to your tumor, please talk to your physician. We encourage all patients to consider genomic testing for their tumor to make sure you have all of the information available before choosing a treatment path.
Your physician can help determine if participating in a clinical trial may be an option for the treatment of your cancer. Your decision to participate in a clinical trial is voluntary and should only be made after all your questions have been answered and you feel comfortable making a well-informed decision.
We are also here to help and provide the information necessary to make an informed decision. You can always contact our medical staff at medicalaffairs@elevationoncology.com or +1 (716) 371-1125. Send us a message, and we’ll get back to you within 48 hours.